Nutritional supplement market growing

Article

The eyecare nutritional supplement market is worth $43.4 million and is projected to grow to $87.4 million within five years, according to research by Frost & Sullivan.

The eyecare nutritional supplement market is worth $43.4 million and is projected to grow to $87.4 million within five years, according to research by Frost & Sullivan.

According to Frost & Sullivan, the impending rapid growth in the market is due to the ageing of the "baby boomer" generation, as well as the recent developments in nutritional supplements for conditions commonly associated with either lifestyle or advanced age, including glaucoma and age-related macular degeneration.

Although nutritional supplements for eye conditions are a relatively new concept, the products Frost & Sullivan assessed included antioxidants such as lutein, beta-carotene, zeaxanthin, astaxanthin, and bilberry.

Despite barriers such as increasing price erosion and variation in international regulations, increased consumer awareness and more validated research into nutritional supplements' efficacy will result in great potential for growth in the market, Frost & Sullivan concluded.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.